Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Report 2019

August 7, 2019

Q1 Report 2019

May 9, 2019

Investor presentations

ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019

Click here for webcast

New York City

Friday, October 4 at 7:45 a.m. Eastern time (ET).

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

ObsEva Investor Presentation – April 2019

ObsEva Short Report 2018

Press Releases

ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways

press release

September 1, 2015

01 Sep 2015 Geneva, Switzerland, 01 September 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs…

Read more

ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study – Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women –

press release

June 23, 2015

Geneva, Switzerland, 23 June 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more

ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour – Positive Safety, Rapid Absorption and Absence of Interaction with Betamethasone is Basis for Phase 2 Study –

press release

February 26, 2015

Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions…

Read more
1 36 37 38 39 40

General Meetings

ObsEva Extraordinary General Meeting 2018

January 28, 2018

Read more

ObsEva Annual General Meeting 2017

June 13, 2017

Read more
1 2

Upcoming Events

Year End 2019 Financial Results week of 02 March 2020

Event

March 2, 2020


Read more

Third Quarter 2019 Financial Results week of 11 November 2019

Event

November 11, 2019


Read more

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

Event

October 17, 2019


Read more
1 2
 

Contacts

ObsEva Switzerland Office

+41 (0)22 552 3840


contact@obseva.ch

ObsEva U.S. Office

+1 857 972 9364


contact@obseva.ch

Media Switzerland & Europe

Christophe Lamps
Dynamics Group
+41 79 476 26 87

cla@dynamicsgroup.ch

Media United States

Marion Janic
RooneyPartners LLC
+1 212-223-4017

mjanic@rooneyco.com

Investor relations




ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.